{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:59:21Z","timestamp":1777661961832,"version":"3.51.4"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The effect of cancer immunotherapy on the endogenous immune response against tumors is largely unknown. Therefore, we studied immune responses against murine tumors expressing the glycoprotein (GP) and\/or nucleoprotein of lymphocytic choriomeningitis virus (LCMV) with or without adoptive T-cell therapy. In nontreated animals, CTLs specific for different epitopes as well as LCMV-GP\u2013specific antibodies contributed to tumor surveillance. Adoptive immunotherapy with monoclonal CTLs specific for LCMV-gp33 impaired the endogenous tumor-specific antibody and CTL response by targeting antigen cross-presenting cells. As a consequence and in contrast to expectations, immunotherapy enhanced tumor growth. Thus, for certain immunogenic tumors, a reduction of tumor-specific B- and T-cell responses and enhanced tumor growth may be an unwanted consequence of adoptive immunotherapy. [Cancer Res 2007;67(15):7467\u201376]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4372","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T14:34:13Z","timestamp":1185978853000},"page":"7467-7476","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Decreased Tumor Surveillance after Adoptive T-Cell Therapy"],"prefix":"10.1158","volume":"67","author":[{"given":"Matthias","family":"Matter","sequence":"first","affiliation":[{"name":"1Tumor Immunology, Department of Clinical Research and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Pavelic","sequence":"additional","affiliation":[{"name":"1Tumor Immunology, Department of Clinical Research and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Pinschewer","sequence":"additional","affiliation":[{"name":"3Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mumprecht","sequence":"additional","affiliation":[{"name":"1Tumor Immunology, Department of Clinical Research and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Eschli","sequence":"additional","affiliation":[{"name":"3Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsanan","family":"Giroglou","sequence":"additional","affiliation":[{"name":"4Applied Virology and Gene Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[{"name":"4Applied Virology and Gene Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Ochsenbein","sequence":"additional","affiliation":[{"name":"1Tumor Immunology, Department of Clinical Research and"},{"name":"2Institute of Medical Oncology, Inselspital, University of Berne, Berne, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2022061623342026500_B1","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science\u20082002; 298: 850\u20134.","DOI":"10.1126\/science.1076514"},{"key":"2022061623342026500_B2","doi-asserted-by":"crossref","unstructured":"Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A\u20082002; 99: 16168\u201373.","DOI":"10.1073\/pnas.242600099"},{"key":"2022061623342026500_B3","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol\u20082005; 23: 2346\u201357.","DOI":"10.1200\/JCO.2005.00.240"},{"key":"2022061623342026500_B4","doi-asserted-by":"crossref","unstructured":"Figlin RA, Thompson, JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol\u20081999; 17: 2521\u20139.","DOI":"10.1200\/JCO.1999.17.8.2521"},{"key":"2022061623342026500_B5","doi-asserted-by":"crossref","unstructured":"Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol\u20082002; 20: 1075\u201386.","DOI":"10.1200\/JCO.2002.20.4.1075"},{"key":"2022061623342026500_B6","doi-asserted-by":"crossref","unstructured":"Khong HT, Restifo NP. Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat Immunol\u20082002; 3: 999\u20131005.","DOI":"10.1038\/ni1102-999"},{"key":"2022061623342026500_B7","doi-asserted-by":"crossref","unstructured":"Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A\u20081998; 95: 1178\u201383.","DOI":"10.1073\/pnas.95.3.1178"},{"key":"2022061623342026500_B8","doi-asserted-by":"crossref","unstructured":"Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med\u20082003; 198: 569\u201380.","DOI":"10.1084\/jem.20030590"},{"key":"2022061623342026500_B9","doi-asserted-by":"crossref","unstructured":"Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol\u20082004; 173: 7125\u201330.","DOI":"10.4049\/jimmunol.173.12.7125"},{"key":"2022061623342026500_B10","doi-asserted-by":"crossref","unstructured":"Burnet FM. Cancer: a biological approach. Br Med J\u20081957; 1: 779\u201386.","DOI":"10.1136\/bmj.1.5022.779"},{"key":"2022061623342026500_B11","doi-asserted-by":"crossref","unstructured":"Shankaran V, Ikeda H, Bruce AT, et al. IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature\u20082001; 410: 1107\u201311.","DOI":"10.1038\/35074122"},{"key":"2022061623342026500_B12","doi-asserted-by":"crossref","unstructured":"Pardoll D. T cells and tumours. Nature\u20082001; 411: 1010\u20132.","DOI":"10.1038\/35082676"},{"key":"2022061623342026500_B13","doi-asserted-by":"crossref","unstructured":"Ku\u0308ndig TM, Bachmann MF, DiPaolo C, et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science\u20081995; 268: 1343\u20137.","DOI":"10.1126\/science.7761853"},{"key":"2022061623342026500_B14","doi-asserted-by":"crossref","unstructured":"Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals, and cross priming in cytotoxic T-cell induction. Nature\u20082001; 411: 1058\u201364.","DOI":"10.1038\/35082583"},{"key":"2022061623342026500_B15","doi-asserted-by":"crossref","unstructured":"Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science\u20081994; 264: 961\u20135.","DOI":"10.1126\/science.7513904"},{"key":"2022061623342026500_B16","doi-asserted-by":"crossref","unstructured":"Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a peripheral solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A\u20081999; 96: 2233\u20138.","DOI":"10.1073\/pnas.96.5.2233"},{"key":"2022061623342026500_B17","doi-asserted-by":"crossref","unstructured":"Ochsenbein AF. Immunological ignorance of solid tumors. Springer Semin Immunopathol\u20082005; 27: 19\u201335.","DOI":"10.1007\/s00281-004-0192-0"},{"key":"2022061623342026500_B18","doi-asserted-by":"crossref","unstructured":"Ehl S, Hombach J, Aichele P, et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J Exp Med\u20081998; 187: 763\u201374.","DOI":"10.1084\/jem.187.5.763"},{"key":"2022061623342026500_B19","doi-asserted-by":"crossref","unstructured":"Pircher H, Bu\u0308rki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature\u20081989; 342: 559\u201361.","DOI":"10.1038\/342559a0"},{"key":"2022061623342026500_B20","doi-asserted-by":"crossref","unstructured":"Chen J, Trounstine M, Alt FW, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol\u20081993; 5: 647\u201356.","DOI":"10.1093\/intimm\/5.6.647"},{"key":"2022061623342026500_B21","doi-asserted-by":"crossref","unstructured":"Pre\u0301vost-Blondel A, Zimmermann C, Stemmer C, Klumburg P, Rosenthal FM, Pircher H. Tumor-infiltration lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol\u20081998; 161: 2187\u201394.","DOI":"10.4049\/jimmunol.161.5.2187"},{"key":"2022061623342026500_B22","doi-asserted-by":"crossref","unstructured":"Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods\u20081999; 223: 77\u201392.","DOI":"10.1016\/S0022-1759(98)00204-X"},{"key":"2022061623342026500_B23","doi-asserted-by":"crossref","unstructured":"Karrer U, Althage A, Odermatt B, et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly\/aly) and spleenless (Hox11\u2212\/\u2212) mutant mice. J Exp Med\u20081997; 185: 2157\u201370.","DOI":"10.1084\/jem.185.12.2157"},{"key":"2022061623342026500_B24","doi-asserted-by":"crossref","unstructured":"Seiler P, Brundler MA, Zimmermann C, et al. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J Exp Med\u20081998; 187: 649\u201354.","DOI":"10.1084\/jem.187.4.649"},{"key":"2022061623342026500_B25","doi-asserted-by":"crossref","unstructured":"Hangartner L, Zellweger RM, Giobbi M, et al. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med\u20082006; 203: 2033\u201342.","DOI":"10.1084\/jem.20051557"},{"key":"2022061623342026500_B26","doi-asserted-by":"crossref","unstructured":"Beyer WR, Miletic H, Ostertag W, von Laer D. Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference. J Virol\u20082001; 75: 1061\u20134.","DOI":"10.1128\/JVI.75.2.1061-1064.2001"},{"key":"2022061623342026500_B27","doi-asserted-by":"crossref","unstructured":"van der Most RG, Murali-Krishna K, Whitton JL, et al. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology\u20081998; 240: 158\u201367.","DOI":"10.1006\/viro.1997.8934"},{"key":"2022061623342026500_B28","doi-asserted-by":"crossref","unstructured":"Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol\u20082005; 17: 195\u2013201.","DOI":"10.1016\/j.coi.2005.02.002"},{"key":"2022061623342026500_B29","doi-asserted-by":"crossref","unstructured":"Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A\u20082005; 102: 9571\u20136.","DOI":"10.1073\/pnas.0503726102"},{"key":"2022061623342026500_B30","doi-asserted-by":"crossref","unstructured":"Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest\u20082005; 115: 1616\u201326.","DOI":"10.1172\/JCI24480"},{"key":"2022061623342026500_B31","doi-asserted-by":"crossref","unstructured":"Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol\u20082004; 5: 141\u20139.","DOI":"10.1038\/ni1029"},{"key":"2022061623342026500_B32","doi-asserted-by":"crossref","unstructured":"Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother\u20082005; 54: 187\u2013207.","DOI":"10.1007\/s00262-004-0560-6"},{"key":"2022061623342026500_B33","unstructured":"Sturmhoefel K, Lee K, Gray GS, et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res\u20081999; 59: 4964\u201372."},{"key":"2022061623342026500_B34","doi-asserted-by":"crossref","unstructured":"Wolpert EZ, Grufman P, Sandberg JK, Tegnesjo A, Karre K. Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J Immunol\u20081998; 161: 4499\u2013505.","DOI":"10.4049\/jimmunol.161.9.4499"},{"key":"2022061623342026500_B35","doi-asserted-by":"crossref","unstructured":"Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol\u20082000; 164: 3095\u2013101.","DOI":"10.4049\/jimmunol.164.6.3095"},{"key":"2022061623342026500_B36","doi-asserted-by":"crossref","unstructured":"Kedl RM, Schaefer BC, Kappler JW, Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol\u20082002; 3: 27\u201332.","DOI":"10.1038\/ni742"},{"key":"2022061623342026500_B37","doi-asserted-by":"crossref","unstructured":"Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition, and T cell affinity maturation. Curr Opin Immunol\u20082003; 15: 120\u20137.","DOI":"10.1016\/S0952-7915(02)00009-2"},{"key":"2022061623342026500_B38","doi-asserted-by":"crossref","unstructured":"Ludewig B, Bonilla WV, Dumrese T, Odermatt B, Zinkernagel RM, Hengartner H. Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol\u20082001; 31: 1772\u20139.","DOI":"10.1002\/1521-4141(200106)31:6<1772::AID-IMMU1772>3.0.CO;2-8"},{"key":"2022061623342026500_B39","doi-asserted-by":"crossref","unstructured":"Yang J, Huck SP, McHugh RS, Hermans IF, Ronchese F. Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci U S A\u20082006; 103: 147\u201352.","DOI":"10.1073\/pnas.0509054103"},{"key":"2022061623342026500_B40","doi-asserted-by":"crossref","unstructured":"Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med\u20081998; 4: 627\u201330.","DOI":"10.1038\/nm0598-627"},{"key":"2022061623342026500_B41","doi-asserted-by":"crossref","unstructured":"Siegel CT, Schreiber K, Meredith SC, et al. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med\u20082000; 191: 1945\u201356.","DOI":"10.1084\/jem.191.11.1945"},{"key":"2022061623342026500_B42","doi-asserted-by":"crossref","unstructured":"Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity\u20082000; 13: 265\u201376.","DOI":"10.1016\/S1074-7613(00)00026-1"},{"key":"2022061623342026500_B43","unstructured":"Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res\u20081999; 59: 1071\u20139."},{"key":"2022061623342026500_B44","doi-asserted-by":"crossref","unstructured":"Cordaro TA, de Visser KE, Tirion FH, et al. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur J Immunol\u20082000; 30: 1297\u2013307.","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1297::AID-IMMU1297>3.0.CO;2-C"},{"key":"2022061623342026500_B45","doi-asserted-by":"crossref","unstructured":"Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors \u201cmelt\u201d from the inside after successful CD8 T cell attack. Eur J Immunol\u20082006; 36: 468\u201377.","DOI":"10.1002\/eji.200526175"},{"key":"2022061623342026500_B46","doi-asserted-by":"crossref","unstructured":"Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med\u20081997; 186: 229\u201338.","DOI":"10.1084\/jem.186.2.229"},{"key":"2022061623342026500_B47","doi-asserted-by":"crossref","unstructured":"Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature\u20082005; 437: 141\u20136.","DOI":"10.1038\/nature03954"},{"key":"2022061623342026500_B48","doi-asserted-by":"crossref","unstructured":"Matsui K, O'Mara LA, Allen PM. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol\u20082003; 15: 797\u2013805.","DOI":"10.1093\/intimm\/dxg078"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7467\/2865659\/7467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7467\/2865659\/7467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T13:00:23Z","timestamp":1683982823000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/15\/7467\/533353\/Decreased-Tumor-Surveillance-after-Adoptive-T-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":48,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4372","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22368149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368152.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368146","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368149.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368146.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495833.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}